China Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), By Therapeutic Class (Chemotherapy, Immunotherapy), And Segment Forecasts, 2024 - 2030

China Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer), By Therapeutic Class (Chemotherapy, Immunotherapy), And Segment Forecasts, 2024 - 2030

China Lung Cancer Therapeutics Market Growth & Trends

The China lung cancer therapeutics market size is anticipated to reach USD 5.34 billion by 2030 and is projected to grow at a CAGR of 13.7% from 2024 to 2030, according to a new study by Grand View Research, Inc. Increasing incidence of lung cancer, growing awareness and screening initiatives, and adoption of targeted therapies in the country is projected to drive the market growth over the forecast years.

In June 2024, the FLAURA2 clinical trial investigated the efficacy of Tagrisso (osimertinib) in combination with chemotherapy compared to standard care for patients with advanced non-small cell lung cancer (NSCLC), particularly focusing on a cohort of Chinese patients. The results demonstrated that this combination therapy significantly reduced the risk of disease progression or death by nearly 50%. This finding is pivotal as it indicates a substantial improvement in patient outcomes, which is anticipated to influence treatment protocols and market dynamics.

The Chinese government has recognized the growing burden of cancer and has taken significant steps to enhance funding and support for research. Initiatives from organizations such as the National Natural Science Foundation of China (NSFC) and the National Major Scientific and Technological Special Project for “Significant New Drugs Development” are aimed at fostering innovation in drug development. This governmental backing is crucial in driving advancements in therapeutics.

China Lung Cancer Therapeutics Market Report Highlights

• Based on disease type, the NSCLC segment led the market with the largest revenue share of 84.27% in 2023, driven by the increasing smoking rates
• Based on therapeutic class, the targeted therapy segment led the market with the largest revenue share of 39.1% in 2023. The growth is attributed to the increasing prevalence of cancer within the population which has created an urgent need for more effective treatment options
• In December 2023, Simcere Zaiming Pharmaceutical Co., Ltd. announced a significant development regarding COSELA (Trilaciclib Hydrochloride for Injection), an innovative oncology product that is co-developed with G1 Therapeutics. The approval notice from the National Medical Products Administration of China (NMPA) for the Supplementary Application of Drugs marks a pivotal moment for this medication, which is designed to improve outcomes for patients

Please note The report will be delivered in 2-3 business days upon order notification.